N-caffeoyldopamine

N-Caffeoyldopamine (Clovamide): A Comprehensive Reference

1. Identity and Chemical Profile

N-Caffeoyldopamine, more formally known as clovamide — i.e., (2S)-3-(3,4-dihydroxyphenyl)-2-[[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]amino]propanoic acid — is also designated as N-caffeoyl-L-3,4-dihydroxyphenylalanine or N-caffeoyl-L-DOPA. It is a derivative of caffeic acid (3,4-dihydroxycinnamic acid) and is structurally an amide isostere of rosmarinic acid. The compound carries the CAS registry number 53755-02-5.

It belongs to a large family of plant phenolamides, comprising compounds derived from the association of phenolic acids with aliphatic or aromatic amines. Due to their many biological activities, phenolamides have garnered scientific interest in the context of their administration for health-improving purposes and their use in the cosmetics industry. They are classified as hydroxycinnamic acid amides (HCAAs), a diverse group of specialized plant phenylpropanoid metabolites involved in maintaining plant tolerance to abiotic and biotic stress.

N-Caffeoyldopamine is a naturally occurring phenolic amide formed by the conjugation of caffeic acid and dopamine. N-Caffeoyldopamine and its natural analogs are synthesized chemically using dopamine and phenylpropenic acids — in this case, caffeic acid. The compound thus unites the catechol moiety of dopamine with the trans-hydroxycinnamic acid moiety of caffeic acid, giving it two catechol-type aromatic rings joined by an amide bond, a feature that underlies much of its radical-scavenging capacity.

The collective term "clovamides" encompasses both cis- and trans-clovamide as well as other clovamide-type substances such as deoxyclovamide, dideoxyclovamide, clovamide methyl ester, and other derivatives. The term "caffedymine" has also appeared in the literature as an alternative trivial name specifically for N-caffeoyldopamine when discussed in the context of its cyclooxygenase-inhibiting activities.

2. Botanical Sources and Natural Occurrence

2.1 Primary Plant Sources

Clovamide (CAS 53755-02-5) was first identified from leaves and stems of red clover (Trifolium pratense L.) in 1974. Clovamide and related hydroxycinnamoyl amides have subsequently been identified in other plants, including Dalbergia melanoxylon Guill. & Perr. (African blackwood) and Theobroma cacao L. (the cocoa tree).

The name "clovamide" directly derives from red clover (Trifolium pratense L.), being the first identified source of this compound. In addition to Theobroma cacao, those compounds are also synthesized, among other things, by Trifolium pallidum clover and Trifolium pratense (red clover), and species of the Capsicum genus.

The highest clovamide content was detected in Trifolium pallidum and amounted to 12.94 mg/g of dry weight, corresponding to 36% of the total content of polyphenolic compounds detected in the examined herbal material originating from this plant. Later studies on clovers confirmed that the Trifolium genus contains species that can be a rich source of clovamide and its methyl ester, the main clovamide derivative detected in plant tissues.

A clovamide content exceeding 21% of the plant extract dry mass was found in extracts from Trifolium clypeatum, T. obscurum, and T. squarrosum, extracted with 80% methanol. Furthermore, different clovamide-type compounds such as cis-clovamide and trans-clovamide, together with caffeoyl-N-tyrosine, coumaroyl-N-tyrosine and feruloyl-N-dopamine, were identified and quantified in that study. It should be noted that clovamide content may vary significantly in plant material originating from different species or even subspecies.

In one phytochemical study, the total phenolic content was higher in red clover (53.7 ± 2.2 mg/g dry weight) than in snow clover (44.4 ± 4.9 mg/g dry weight). Red clover contained higher amounts of clovamide (15.6 ± 0.6 mg/g dry weight, respectively) than snow clover (8.2 ± 0.1 mg/g dry weight).

In the aerial parts of T. pratense, trans-clovamide is synthesized and accumulated at a relatively high level, being attained at up to around 1% of dry matter, with its content dependent on the genotype.

2.2 Cocoa and Dietary Exposure

In the human diet, clovamides are mainly present in chocolate and other cocoa-containing products. The clovamide content in cocoa beans varies depending on the geographic origin of cocoa, ranging from 1.36 up to 2.64 mg/kg in unroasted fermented beans (dry weight), and is drastically reduced after roasting.

Clovamide is present at 1.4–2.6 mg/kg in cocoa powder from unroasted beans, and 0.6–1.3 mg/kg in roasted powder. Cocoa hulls, obtained as a by-product after pre-roasting of whole beans, are rich in phenolic antioxidants and contain interesting amounts of clovamide (in the range of 1.817 ± 0.059 mg/kg, dry weight).

Like other N-phenylpropenoyl amino acids naturally occurring in cocoa, clovamide contributes to the astringent taste of unfermented cocoa beans as well as roasted cocoa nibs. The sensation induced by these amides in the oral cavity was described as mouth-drying and puckering astringent.

2.3 Plant Role and Biosynthesis

In planta, high levels of phenolic compounds like clovamide may play a role in protecting plants from biotic (e.g., pathogenesis and herbivory) and abiotic stresses (e.g., UV radiation and ozone). Consistent with a role in protecting the plant from biotic stresses is the observation that clovamide accumulates in red clover roots in response to jasmonic acid treatment. In disease-tolerant cacao genotypes, the most abundant metabolite feature was clovamide, which was up to approximately 58-fold higher in tolerant leaves compared to susceptible genotypes.

3. Traditional and Historical Use

Although this compound was identified as early as the 1970s, scientific interest in its biological activity was marginal at that time. However, recent decades have provided numerous reports dealing with newly identified plant sources as well as the beneficial properties of clovamide and its related compounds.

Despite a growing interest in the biological activity of natural polyphenolic substances, studies on the properties of clovamide and related compounds, their significance as bioactive components of the diet, as well as their effects on human health are a relatively new research trend. On the other hand, in vitro and in vivo evidence indicates the considerable potential of these substances in the context of maintaining human health or using them as pharmacophores.

The botanical sources of N-caffeoyldopamine — particularly red clover (Trifolium pratense) and cocoa (Theobroma cacao) — both have documented histories of traditional use, though these traditions predate the identification of N-caffeoyldopamine specifically as a constituent. Numerous plants, including clovers, have been widely used in folk medicine for the treatment of different disorders. Caffeic acid is widely found in many medicinal herbs, such as Echinacea and artichoke, and has been used for centuries in herbal remedies for its antioxidant and anti-inflammatory properties.

It is important to note that, as a specific isolated phytochemical, N-caffeoyldopamine itself was not the object of traditional medicinal use. Its occurrence in traditionally used plants (red clover, cocoa) is established, but it was not recognized as an individual bioactive constituent until the late twentieth century. No historical monographs or ethnopharmacological traditions are documented for N-caffeoyldopamine as a discrete entity.

4. Chemical Structure, Key Constituents, and Structural Analogs

N-Caffeoyldopamine, along with its natural analogs N-cinnamoyldopamine, N-coumaroyldopamine, N-feruloyldopamine, and N-sinapoyldopamine, possesses chemical structural moieties found in β-adrenergic drugs such as dobutamine and denopamine. The chemical structures of these analogs differ in the positions and number of hydroxyl groups on the benzene ring.

The structural distinction of N-caffeoyldopamine from its closest analogs resides in the catechol (3,4-dihydroxy) substitution pattern on both aromatic rings — the dopamine-derived ring and the caffeic acid-derived ring — giving the molecule four phenolic hydroxyl groups in total. This high degree of hydroxylation underpins its potent radical-scavenging properties. Antioxidant studies on clovamide led to the conclusion that it is a powerful oxygen radical scavenger, partially contributed by its molecular catechol moieties.

The major mass/charge (m/z) signal for N-caffeoyldopamine in LC-MS was obtained at an estimated m/z of 315.1.

5. Established Mechanisms of Action

5.1 Beta-2 Adrenoceptor Agonism and cAMP Elevation

N-Caffeoyldopamine and its natural analogs were synthesized and investigated to determine their potency as β-adrenoceptor agonists, because they have chemical structural moieties found in β-adrenoceptor agonists. Among the compounds tested, N-coumaroyldopamine and N-caffeoyldopamine were the two most potent compounds, able to increase cyclic adenosine monophosphate (cAMP) at concentrations below 0.05 µM in U937 cells.

Using beta-2-specific antagonists (butoxamine and ICI 118551), N-coumaroyldopamine and N-caffeoyldopamine were found to increase cAMP via beta-2-adrenoceptors in U937 cells. In producing cAMP in U937 cells, N-coumaroyldopamine and N-caffeoyldopamine were as potent as several well-known beta-2-adrenoceptor agonists (salbutamol, procaterol, and fenoterol).

The decreasing order of potency across the analogs was: N-coumaroyldopamine > N-caffeoyldopamine > N-feruloyldopamine > N-sinapoyldopamine > N-cinnamoyldopamine.

5.2 Cyclooxygenase (COX) Inhibition

Previous studies indicated that caffedymine (N-caffeoyldopamine) inhibits P-selectin expression via increasing cAMP through beta-2 adrenoceptors, but the inhibition was only partially repressed by beta-2 adrenoceptor antagonists, suggesting additional mechanisms underlying the inhibitory effect. Therefore, the effect of caffedymine and its analogues on COX enzymes (I and II) was investigated, because COX enzymes are deeply involved in regulating P-selectin expression on human platelets.

The decreasing order of COX-I inhibitory activity was: caffedymine > N-caffeoyltyramine > N-feruloyltyramine > N-coumaroyltyramine > N-cinnamoyltyramine. Caffedymine was the most potent compound tested, able to inhibit COX-I enzyme activity by 43% (P < 0.013) at the concentration of 0.01 µM.

5.3 Free Radical Scavenging and Antioxidant Activity

Reports in the literature indicate the considerable antioxidant potential of clovamide when compared to many other well-described phenolic antioxidants of plant origin. Clovamide displayed an ability to scavenge 2,2-diphenyl-1-picrylhydrazyl radicals (DPPH•) that is comparable to that of rosmarinic and caffeic acids, and even exceeded the effectiveness of butylated hydroxyanisole (BHA), a synthetic antioxidant used as a food additive (E320).

In the prevention of the oxidation of sunflower oil triacylglycerols, caffeoyldopamine (clovamide), cinnamoyldopamine, p-coumaroyldopamine, feruloyldopamine, sinapoyldopamine, caffeoyltyramine, and caffeoyltryptamine all displayed comparable or higher antioxidant activity than caffeic acid (a reference compound). Moreover, in that test, clovamide was the most efficient one.

In a 2018 study, N-trans-caffeoyldopamine was tested for antioxidant activity by scavenging DPPH• and ABTS•+ radicals, by reducing ferric ions, and by ferrous ion chelation. Both synthesized hydroxycinnamates (including N-trans-caffeoyldopamine) were found to be better antioxidants than the parent acids in the in vitro tests applied.

5.4 NF-κB and PPARγ Modulation / Anti-inflammatory Signaling

Researchers investigated the anti-inflammatory potential of clovamide (a N-phenylpropenoyl-L-amino acid amide present in cocoa beans) and two phenolic extracts from unroasted and roasted cocoa beans, by evaluating superoxide anion (O₂⁻) production, cytokine release, and NF-κB activation in human monocytes stimulated by phorbol 12-myristate 13-acetate (PMA).

Clovamide and rosmarinic acid inhibited PMA-induced O₂⁻ production and cytokine release (with a bell-shaped curve and maximal inhibition at 10–100 nM), as well as PMA-induced NF-κB activation; the two cocoa extracts were less effective. In all tests, clovamide was the most potent compound and also enhanced peroxisome proliferator-activated receptor-γ (PPARγ) activity, which may exert anti-inflammatory effects.

5.5 p56^lck SH2 Domain Binding

Clovamide also showed a remarkable binding affinity for the p56^lck SH2 domain, so highlighting interesting properties for the treatment of a broad range of human diseases such as cancer, autoimmune disease, osteoporosis, and chronic inflammatory disease. This interaction, identified in in vitro binding studies, connects N-caffeoyldopamine to signaling pathways governed by Src-family tyrosine kinases, though no clinical or animal studies have yet confirmed therapeutic relevance of this mechanism.

5.6 Neuroprotective Mechanisms

In a 2009 British Journal of Pharmacology study, three in vitro models of neuronal death were selected: (i) differentiated SH-SY5Y human neuroblastoma cells exposed to tert-butylhydroperoxide (t-BOOH) for oxidative stress; (ii) differentiated SK-N-BE(2) human neuroblastoma cells treated with L-glutamate for excitotoxicity; and (iii) differentiated SH-SY5Y cells exposed to oxygen-glucose deprivation/reoxygenation for ischaemia-reperfusion.

Both clovamide and rosmarinic acid (10–100 µmol·L⁻¹) significantly protected neurons against insults with similar potencies and efficacies. The EC₅₀ values were in the low micromolar range (0.9–3.7 µmol·L⁻¹), while the maximal effects ranged from 40% to 60% protection from cell death over the untreated control at 100 µmol·L⁻¹. These effects were mediated by the prevention of oxidative stress, intracellular Ca²⁺ overload, and c-fos expression.

6. Scientific Evidence by Area of Use

6.1 Antioxidant Activity

Evidence level: In vitro and ex vivo; preliminary.

Clovamide represents an interesting compound for its remarkable antioxidant activity. It was shown that clovamide has antiradical properties similar to rosmarinic acid and caffeic acid, resulting more effective than other well-known antioxidants such as epicatechin, trolox, kaempferol, and butylated hydroxyanisole (BHA).

Antioxidant activities of clovamide and cocoa extracts were investigated by measuring superoxide radical scavenging capabilities in a Rotating Ring-Disk Electrode (RRDE) electrochemical system against in-situ generated superoxide radical. The studies concluded a positive correlation between clovamide concentration and the overall antioxidant activities of beans, with the roasting step showing a reduction effect on both.

The results confirmed a significant protective effect of clovamide on liposomal model systems. All antioxidant studies to date are in vitro or used isolated liposomal/chemical model systems. No human clinical trials have been conducted to evaluate the antioxidant effects of isolated N-caffeoyldopamine in vivo.

6.2 Anti-inflammatory Activity

Evidence level: In vitro (human cell lines); preliminary.

The most detailed mechanistic study of anti-inflammatory activity used primary human monocytes as the cellular model. Clovamide and rosmarinic acid inhibited PMA-induced O₂⁻ production and cytokine release, with a bell-shaped curve and maximal inhibition at 10–100 nM, as well as PMA-induced NF-κB activation; the two cocoa extracts were less effective. The study employed ex vivo human cells stimulated with a pharmacological inducer (PMA), lending it greater physiological relevance than purely cell-line-based assays, but it does not constitute clinical evidence in human subjects.

Cocoa extracts have been noted in vitro to downregulate inflammatory cytokines from macrophages including MCP-1, TNF-α, and IL-6 with a potency greater than a similar concentration of pure (−)-epicatechin. Other studies have noted that the isolated cocoa constituent clovamide has similar effects in LPS-stimulated macrophages.

6.3 Cardiovascular and Antiplatelet / Antithrombotic Activity

Evidence level: In vitro (human blood) and in vivo (mouse model); preliminary, no human trials.

N-Coumaroyldopamine and N-caffeoyldopamine were investigated to determine their effects on P-selectin expression and platelet-leukocyte interactions in vitro and in vivo models. At the concentration of 0.05 µM, they were able to inhibit P-selectin expression on platelets by 33% and 30% respectively (P < 0.011 and P < 0.012). The inhibition was partially blocked by β2-adrenoceptor antagonists, suggesting that β2 receptors are probably engaged in the inhibition.

N-Caffeoyldopamine and N-coumaroyldopamine could also suppress platelet-leukocyte interactions in blood samples by 36% and 32% respectively (P < 0.013 and P < 0.011), at the same concentration (0.05 µM).

In an animal study, mice administered orally with N-caffeoyldopamine (50 and 100 µg/35 g of body weight) also showed great reduction in P-selectin expression and platelet-leukocyte interactions by 31 to 45% (P < 0.011) and 34 to 43% (P < 0.014), respectively. These data suggest that the clovamide-type phenylpropenoic acid amides are able to suppress platelet-leukocyte interactions via inhibiting P-selectin expression.

Caffedymine (N-caffeoyldopamine), a clovamide-type substance, was found to suppress the activity of platelet cyclooxygenase (COX) and the expression of P-selectin on platelet membrane. These findings come from in vitro human platelet assays and a single mouse model; there are no human clinical trials evaluating N-caffeoyldopamine as an antiplatelet or antithrombotic agent.

6.4 Neuroprotective Activity

Evidence level: In vitro (human neuroblastoma cell lines); preliminary, no animal or human studies reported for the isolated compound.

Three different in vitro models were selected for investigating neuroprotection: (i) differentiated SH-SY5Y human neuroblastoma cell lines exposed to tert-butylhydroperoxide (t-BOOH; 100 µmol·L⁻¹, 3 h), as a model of oxidative stress; (ii) differentiated SK-N-BE(2) human neuroblastoma cell lines treated with L-glutamate (1 mmol·L⁻¹, 24 h), as a model of excitotoxicity; and (iii) differentiated SH-SY5Y human neuroblastoma cell lines exposed to oxygen-glucose deprivation (OGD; 5 h)/reoxygenation, as a model of ischaemia-reperfusion injury.

The data demonstrated that both clovamide and rosmarinic acid protect neurons against different harmful stimuli by mechanisms presumably related to their ability to prevent t-BOOH-induced oxidative stress and L-glutamate-induced intracellular Ca²⁺ overload/c-fos expression.

The synthesis and biological evaluation of clovamide analogs showed that they have potent anti-neuroinflammatory effects by reducing the expression of GFAP (glial fibrillary acidic protein) in a model of Parkinson's disease. This evidence points toward potential relevance in neuroinflammatory contexts, but all current data is confined to cell culture and analogue studies; in vivo and clinical neuroprotective studies with N-caffeoyldopamine itself have not been reported.

6.5 Acetylcholinesterase Inhibition

Evidence level: In vitro and in silico; preliminary.

Two amides derived from trans-caffeic/ferulic acid and dopamine were synthesized and characterized. The compounds were tested for the inhibition of acetylcholinesterase (AChE) from Electrophorus electricus and for antioxidant activity by scavenging DPPH• and ABTS•+ radicals, reducing ferric ions, and ferrous ion chelation. N-trans-Feruloyldopamine displayed the highest inhibitory effect on AChE with an IC₅₀ value of 8.52 µM.

N-trans-Caffeoyldopamine also showed AChE inhibitory activity in this study, though with lower potency than its feruloyl analog. All these findings make N-trans-caffeoyldopamine and N-trans-feruloyldopamine interesting bioactive compounds for pharmaceutical and food research as potentially useful ingredients of medicines. Phenolic acids and their derivatives found in nature are well-known for their potential biological activity. The relevance of in vitro AChE inhibition to clinical cognition-related outcomes has not been established for this compound.

6.6 Anticancer and Antiproliferative Properties

Evidence level: Molecular binding studies and in vitro; very preliminary.

Clovamide showed a remarkable binding affinity for the p56^lck SH2 domain, highlighting interesting properties for the treatment of a broad range of human diseases such as cancer, autoimmune disease, osteoporosis, and chronic inflammatory disease. The reference literature on clovamide and its derivatives points to their antioxidative, antiplatelet (antithrombotic), anti-inflammatory, and even anticancer action. Specific in vitro anticancer studies with N-caffeoyldopamine as an isolated agent are limited; available mechanistic data relates primarily to the compound's structural interaction with kinase signaling domains and its capacity to inhibit inflammatory mediators that are co-implicated in oncogenesis. No animal tumor models or clinical oncology data have been published.

7. Body Systems and Health Areas Associated with N-Caffeoyldopamine

Based on the available literature, N-caffeoyldopamine has been investigated in connection with the following body systems and health domains:

• Cardiovascular system: The literature reports deal with the antioxidant, anti-inflammatory, neuroprotective, antiplatelet/antithrombotic, and anticancer properties of clovamide-type compounds. The antiplatelet activity via P-selectin suppression and COX inhibition is the most mechanistically characterized cardiovascular effect.
• Nervous system: In vitro neuroprotective activity against oxidative stress, excitotoxicity, and ischaemia-reperfusion injury has been demonstrated in human neuroblastoma cell models. AChE inhibitory activity has also been reported, indicating potential relevance to cholinergic signaling.
• Immune and inflammatory system: Inhibition of NF-κB activation, suppression of superoxide and cytokine production in human monocytes, and enhancement of PPARγ activity reflect immunomodulatory properties at cellular level.
• Metabolic and lipid oxidation: A positive correlation between clovamide concentration and the overall antioxidant activities of beans was found, with the roasting step showing a reduction effect on both. Protective effects in liposomal lipid peroxidation systems suggest potential relevance to lipid metabolism, though no direct metabolic outcomes in humans have been assessed.
• Skin / cosmetics: Due to their many biological activities, phenolamides have garnered scientific interest in the context of their administration for health-improving purposes and their use in the cosmetics industry.

8. Bioavailability and Pharmacokinetics

Clovamides are characterized by a low threshold for perceptible astringent effects (concentrations > 10 µmol/L), and therefore their ingestion may evoke astringent effects in the mouth. Contrary to the well-established blood plasma levels of flavonoids and phenolic acids or their metabolites, data on the bioavailability and metabolism of clovamide(s) are limited. Given the ample evidence on other low-molecular-weight polyphenols (including phenolic acids), it can be assumed that the maximal plasma levels of clovamides and their metabolites range from nanomoles to a few micromoles per liter.

Another aspect is the bioavailability of clovamide(s), especially in the context of neuroprotective activity, and prospects for overcoming this obstacle. The blood-brain barrier penetration of N-caffeoyldopamine has not been characterized in published pharmacokinetic studies; the extent to which plasma levels achievable through dietary or supplemental intake would correspond to the concentrations active in cell-based neuroprotection assays (EC₅₀ 0.9–3.7 µmol·L⁻¹) remains unknown.

9. Forms and Preparations

N-Caffeoyldopamine does not currently have a standalone standardized pharmaceutical or dietary supplement form supported by clinical dosing guidelines. It is encountered in the following contexts:

• Dietary intake via cocoa products: In the human diet, clovamides are mainly present in chocolate and other cocoa-containing products. Unroasted or minimally processed cocoa retains higher levels than roasted or alkalized cocoa.
• Red clover extracts: Commercial red clover (Trifolium pratense) extracts — commonly standardized for isoflavone content — also contain clovamide, though this compound is rarely the basis of standardization in commercially available products.
• Research-grade material: Trans-clovamide, for use as a standard, is available from commercial chemical suppliers such as Santa Cruz Biotechnology. This form is used exclusively for analytical and laboratory research purposes, not as a consumer supplement.
• Synthesized compound: In research settings, N-caffeoyldopamine is synthesized by dissolving the appropriate phenylpropenic acid (caffeic acid) in dichloromethane and converting it to the symmetrical anhydride with 1,3-diisopropylcarbodiimide, followed by reaction with dopamine.

10. Dosages Reported in Studies

No standardized or recommended human dosage for isolated N-caffeoyldopamine exists. The following concentrations and doses were reported in the experimental literature:

• In U937 myelocytic cell studies, N-caffeoyldopamine was able to increase cAMP at concentrations below 0.05 µM.
• In platelet and whole-blood assays, N-caffeoyldopamine inhibited P-selectin expression by 30% and suppressed platelet-leukocyte interactions by 36% at a concentration of 0.05 µM.
• In the in vivo mouse antiplatelet study, oral administration at 50 µg and 100 µg per 35 g body weight produced significant reductions in P-selectin expression and platelet-leukocyte interactions.
• In the COX inhibition study, caffedymine inhibited COX-I enzyme activity by 43% at the concentration of 0.01 µM.
• In the neuroprotection study (Fallarini et al., 2009), both clovamide and rosmarinic acid (10–100 µmol·L⁻¹) significantly protected neurons, with EC₅₀ values in the low micromolar range (0.9–3.7 µmol·L⁻¹), while maximal effects ranged from 40% to 60% protection from cell death at 100 µmol·L⁻¹.
• In the human monocyte anti-inflammatory study, maximal inhibition of O₂⁻ production and cytokine release was observed at 10–100 nM of clovamide.

11. Safety Considerations and Interactions

Formal toxicological profiling, maximum tolerated dose studies, or safety pharmacology studies for isolated N-caffeoyldopamine in humans have not been published in the peer-reviewed literature identified in this review. The following points are supported by the available evidence:

• Astringency at elevated concentrations: Clovamides are characterized by a low threshold for perceptible astringent effects (concentrations > 10 µmol/L), and therefore their ingestion may evoke astringent effects in the mouth.
• Beta-2 adrenoceptor agonism: N-Caffeoyldopamine was found to increase cAMP via beta-2-adrenoceptors in U937 cells, with potency comparable to well-known beta-2-adrenoceptor agonists (salbutamol, procaterol, and fenoterol). This mechanism implies theoretical relevance for individuals using cardiac or bronchodilatory beta-adrenergic drugs; however, no pharmacological interaction data in humans have been reported.
• COX inhibition: Previous studies indicate that caffedymine inhibits P-selectin expression via increasing cAMP through beta-2 adrenoceptors, but the inhibition was only partially repressed by beta-2 adrenoceptor antagonists, suggesting additional mechanisms. The observed in vitro COX-I inhibitory activity suggests potential pharmacodynamic interactions with other antiplatelet agents (e.g., aspirin), though this has not been investigated experimentally in animals or humans.
• Dopamine structural moiety: The dopamine-containing backbone raises theoretical questions regarding its metabolic fate — including whether it may be subject to monoamine oxidase (MAO)-mediated catabolism — but this has not been investigated pharmacokinetically. No MAO interaction studies have been published.
• Limited bioavailability data: Data on the bioavailability and metabolism of clovamide(s) are limited. Given evidence on other low-molecular-weight polyphenols, it can be assumed that the maximal plasma levels of clovamides and their metabolites range from nanomoles to a few micromoles per liter. Whether orally consumed N-caffeoyldopamine reaches active concentrations at tissue target sites in humans is unresolved.
• Research stage: Studies on the properties of clovamide and related compounds, their significance as bioactive components of the diet, as well as their effects on human health are a relatively new research trend. In vitro and in vivo evidence indicates considerable potential of these substances in the context of maintaining human health or using them as pharmacophores. No human safety or tolerability studies have been conducted for N-caffeoyldopamine as an isolated supplement.

12. Overall Evidence Assessment

Neuroprotective effects and anti-inflammatory properties of clovamide have been demonstrated in vitro. All these findings make clovamide an interesting bioactive compound for pharmaceutical and food research, potentially useful as a nutraceutical ingredient.

The totality of evidence for N-caffeoyldopamine remains at an early preclinical stage as of 2024. The compound has documented and mechanistically characterized activity in: (1) cell-free radical-scavenging assays, (2) human cell lines (monocytes, neuroblastoma, U937), (3) human whole-blood platelet assays, and (4) one in vivo mouse antiplatelet model. The biological activities most strongly supported by replicated studies are beta-2 adrenoceptor agonism, COX-I inhibition, antioxidant radical scavenging, NF-κB/PPARγ modulation in human monocytes, and in vitro neuroprotection. It is suggested that, in the future, these properties might be utilized in the food and cosmetic industry as well as when developing new prophylactic and therapeutic strategies to protect human health. No randomized controlled trials, pharmacokinetic studies in humans, or defined clinical dosing regimens have been published for N-caffeoyldopamine as an isolated compound.

References

• Clovamide and Its Derivatives—Bioactive Components of Theobroma cacao and Other Plants in the Context of Human Health. Foods, 2024. PubMed PMID: 38611422
• Clovamide and Its Derivatives—Bioactive Components of Theobroma cacao and Other Plants in the Context of Human Health. PMC Full Text (PMC11011365)
• Park JB. N-Coumaroyldopamine and N-caffeoyldopamine increase cAMP via beta 2-adrenoceptors in myelocytic U937 cells. FASEB J. 2005 Apr;19(6):497-502. PubMed PMID: 15790999
• Park JB, Schoene N. Clovamide-type phenylpropenoic acid amides, N-coumaroyldopamine and N-caffeoyldopamine, inhibit platelet-leukocyte interactions via suppressing P-selectin expression. J Pharmacol Exp Ther. 2006;317(2):813-9. PubMed PMID: 16478826
• Park JB. Caffedymine from Cocoa Has COX Inhibitory Activity Suppressing the Expression of a Platelet Activation Marker, P-Selectin. J Agric Food Chem. 2007 Mar 21;55(6):2171-5. ResearchGate
• Fallarini S, Miglio G, Paoletti T, et al. Clovamide and rosmarinic acid induce neuroprotective effects in in vitro models of neuronal death. Br J Pharmacol. 2009 Jul;157(6):1072-84. PMC2737666
• Zeng Q, et al. Anti-inflammatory Properties of Clovamide and Theobroma cacao Phenolic Extracts in Human Monocytes: Evaluation of Respiratory Burst, Cytokine Release, NF-κB Activation, and PPARγ Modulation. J Agric Food Chem. 2011
• Dizdar M, et al. Acetylcholinesterase Inhibition and Antioxidant Activity of N-trans-Caffeoyldopamine and N-trans-Feruloyldopamine. Sci Pharm. 2018;86(2):11. PMC6027674
• Locatelli M, et al. Clovamide and phenolics from cocoa beans (Theobroma cacao L.) inhibit lipid peroxidation in liposomal systems. Food Res Int. 2013
• Sullivan ML, et al. Red Clover HDT, a BAHD Hydroxycinnamoyl-Coenzyme A:L-DOPA Hydroxycinnamoyl Transferase That Synthesizes Clovamide. Front Plant Sci. 2021. PMC8641662
• Clovamide, a Hydroxycinnamic Acid Amide, Is a Resistance Factor Against Phytophthora spp. in Theobroma cacao. PMC7786005
• Tava A, et al. Clovamide and Flavonoids from Leaves of Trifolium pratense and T. pratense subsp. nivale Grown in Italy. PubMed PMID: 26197520
• Arlorio M, et al. Roasting impact on the contents of clovamide (N-caffeoyl-L-DOPA) and the antioxidant activity of cocoa beans (Theobroma cacao L.). ResearchGate
• Examine.com. Cocoa Extract Research Summary. (Clovamide quantification data in cocoa products)
• Frontiers in Cell and Developmental Biology. Genetic Imaging of Neuroinflammation in Parkinson's Disease: Recent Advancements. 2021 (clovamide analog anti-neuroinflammatory reference)